You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)旗下創新藥研發附屬軒竹生物引入陽光人壽等12名投資者
阿思達克 01-03 08:41
四環醫藥(00460.HK)公佈,陽光人壽保險、晉江軒弘三號股權投資合夥企業及中銀資本投資控股等12名投資者,認購公司旗下軒竹生物科技(目標公司)發行的3,980.9萬股,佔其擴大後股本8.83%,總代價爲6.11億元人民幣(約7.47億港元)。 於增資事項完成後,公司於目標公司的股權將由68.44%攤薄至約62.39%,且目標公司將繼續作爲公司的間接非全資附屬。 目標公司爲集團的創新藥研究與開發附屬,具備從小分子及大分子藥物臨牀前開發到臨牀開發、註冊及商業化的綜合研發能力。目標公司主要從事創新藥研發,聚焦於腫瘤、代謝及消化等多個治療領域。 集團計劃將增資事項所得款項用於進一步開發集團的中後期臨牀試驗產品管線及引進更多後期產品項目,以期集團能夠爲中國患者提供更新更優的治療方案。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account